{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT07365995","nct_id":"NCT07365995","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct07365995. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"BNT324","type":"EXPERIMENTAL"},{"description":null,"label":"Docetaxel plus prednisone/ prednisolone","type":"ACTIVE_COMPARATOR"}],"collaborators":["BioNTech (Shanghai) Pharmaceuticals Co., Ltd.","DualityBio Inc."],"completion_date":{"date":"2031-02","type":"ESTIMATED"},"conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":{"count":736,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"BNT324","otherNames":["DB-1311"],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"},{"name":"Prednisone/prednisolone","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-16","lead_sponsor":"BioNTech SE","official_title":"A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2031-02","type":"ESTIMATED"},"primary_outcomes":[{"measure":"rPFS assessed by BICR","timeFrame":"From randomization to end of study, i.e., up to 58 months"},{"measure":"OS","timeFrame":"From randomization to end of study, i.e., up to 58 months"}],"references":[],"start_date":{"date":"2026-04-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT07365995"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct07365995"}